Shaji Kumar, MD, Discusses 5-Year Overall Survival Data for MM Daratumumab Combo in the MAIA Study

Video

At EHA 2021, Shaji Kumar, MD, reflects on the significance of 5-year data from the MAIA study of daratumumab plus lenalidomide/dexamethasone in patients with newly diagnosed multiple myeloma.

CancerNetwork® sat down with Shaji Kumar, MD, from the Mayo Clinic at the 2021 European Hematology Association (EHA) Congress to talk about overall survival for patients with transplant-ineligible newly diagnosed multiple myeloma who were treated with daratumumab (Darzalex) plus lenalidomide (Revlimid) and dexamethasone compared with lenalidomide and dexamethasone alone in the phase 3 MAIA trial (NCT02252172). At 5 years of follow-up, there was a significant reduction in the risk of death for patients taking both drug combinations.

Transcript:

This the first time that we have seen a difference in overall survival reported on this study. Obviously, with overall survival, we had to wait for much more mature data. With the current follow-up, what we see is that the 5-year overall survival [rates] for the daratumumab plus lenalidomide and dexamethasone was 66% compared with 53% for the lenalidomide and dexamethasone, which is, again, a significant improvement, or a 30% to 32% reduction in the risk of death when you use a 3-drug combination compared to the 2-drug combination.

Reference

Theirry F, Kumar S, Torben P, et al. Overall survival results with daratumumab, Lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study. Presented at: 2021 European Hematology Association Annual Meeting; June 9-17, 2021; Virtual; Abstract LB1901. Accessed June 29, 2021. https://bit.ly/3hmf7l9

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Related Content